Advertisement
Product › Details
MVA-BN® technology (Modified Vaccinia Ankara)
Next higher product group | vaccine technology | |
Status | 2005-07-06 production/use existent | |
Organisation | Bavarian Nordic GmbH | |
Group | Bavarian Nordic (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for MVA-BN® technology (Modified Vaccinia Ankara)
- [1] Bavarian Nordic A/S. (11/1/18). "Press Release: Henrik Juuel Joins Bavarian Nordic as Chief Financial Officer". Copenhagen....
- [2] Bavarian Nordic A/S. (5/31/18). "Press Release: Bavarian Nordic Announces Appointment of Henrik Juuel as Chief Financial Officer". Copenhagen....
- [3] Bavarian Nordic A/S. (5/2/18). "Press Release: Bavarian Nordic Receives FDA Orphan Drug Designation for BN-Brachyury for the Treatment of Chordoma". Copenhagen....
- [4] Bavarian Nordic A/S. (3/16/18). "Press Release: Bavarian Nordic Announces Partnership with U.S. Department of Defense to Combat Equine Encephalitis Virus". Copenhagen....
- [5] Bavarian Nordic A/S. (3/12/18). "Press Release: Bavarian Nordic Announces Annual Report 2017". Copenhagen....
- [6] Bavarian Nordic A/S. (1/31/18). "Press Release: Bavarian Nordic Announces the Planned Departure of Chief Financial Officer, Ole Larsen". Copenhagen....
- [7] Bavarian Nordic A/S. (8/25/17). "Press Release: Bavarian Nordic Announces First Half 2017 Results". Copenhagen....
- [8] Bavarian Nordic A/S. (7/27/17). "Press Release: Bavarian Nordic Announces Agreement with Janssen for the Development of Vaccine Regimens against HIV-1 and Hepatitis B". Copenhagen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top